Cardiovascular diseases (CVD) remain the leading cause of disease burden , causing one in three deaths worldwide as a result of population growth, population aging and exposure to a broad range of ...

Inflammation plays a central role in the pathogenesis of atherosclerosis and cardiovascular disease. 1 Atherosclerosis in particular is an inflammatory process that involves endothelial dysfunction, ...

Health care professionals should explore the use of glucagon-like peptide-1 receptor agonists (GLP1RAs) for cardiovascular risk reduction and their broader impacts on cardiometabolic health beyond ...

A newly released ACC Expert Consensus Decision Pathway (ECDP) focused on the clinical assessment, management and trajectory of patients hospitalized with heart failure (HF) includes revisions to the ...

In the ABYSS (Assessment of Beta-Blocker Interruption 1 Year After an Uncomplicated Myocardial Infarction on Safety and Symptomatic Cardiac Events Requiring Hospitalization) trial, interruption of ...

Young Scholars Alumni at ACC.24 in Atlanta. Young Scholars Describe Their Experience at ACC.22 in Washington, DC. The ACC Young Scholars Program is designed for high school students who are interested ...

The ACC is dedicated to creating a strong, diverse and inclusive field of future cardiovascular physicians, scientists and professionals. The ACC's Internal Medicine and Pediatric Cardiology Program ...

In-hospital initiation of dapagliflozin in patients hospitalized for acute heart failure (HF) did not significantly reduce the short-term risk of worsening HF or death, based on findings from the DAPA ...

The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure (HF) or death from any cause among patients with an increased risk for HF following acute ...

Beta-blocker therapy following myocardial infarction (MI) was the primary focus of a hot line session at ESC Congress 2025. Study investigators presented findings from the REBOOT-CNIC and ...

Digitoxin is beneficial in reducing the combined risk of heart failure (HF) hospitalization and all-cause mortality in patients with systolic HF. Maintaining serum digitoxin levels in a narrow ...

YOU ARE HERE: Home > Guidelines and Clinical Policy > 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes ...